Key facts
- It has raised $5.2M; the latest was Early Stage VC ($5.2M) in Feb 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for PharmAI Discovery
- ·The full record, as it builds
Funding rounds
No funding rounds for PharmAI Discovery are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PharmAI Discovery
Developer of an AI-integrated drug discovery system designed for identifying and advancing small-molecule therapeutics targeting complex protein interactions. The company's platform combines atomic-level screening, medicinal chemistry, radiolabeling, and in vivo validation within a single pipeline, enabling pharmaceutical and biotech organizations to generate ready assets with higher hit rates, reduced development risk, and accelerated timelines from target identification to clinical trials.
- Sector
- Healthcare
- HQ
- Dresden, Germany
- Founded
- 2020
- Employees
- 8
- Website
- pharmai-discovery.com/
- Ownership
- Privately Held (backing)
PharmAI Discovery doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PharmAI Discovery shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PharmAI Discovery in its N-PORT filings yet. We sweep new filings monthly.